Safety and Efficacy of QAX576 in Adults With Moderate Persistent Allergic Asthma
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00598104
Recruitment Status :
(Due to the lack of enrolment and complexity of design, this study in asthma was terminated. No subjects have been dosed for this study.)
A Randomized, Double-blinded, Placebo Controlled, Parallel Group, Multi-center Study to Assess Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Efficacy of Intravenous Doses of QAX576 in Moderate Persistent Allergic Asthmatics Following Inhaled Corticosteroid Withdrawal
Study Start Date :
Actual Primary Completion Date :
Resource links provided by the National Library of Medicine
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years to 55 Years (Adult)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
History of asthma attacks
Taking inhaled corticosteroids
Women of child-bearing potential
History of respiratory disease other than asthma
History of severe allergy to food or drugs
Previous use of monoclonal antibodies
Very low or high body weight
Other protocol-defined inclusion/exclusion criteria may apply.